



Javelin Pharmaceuticals to Announce Third Quarter 2009 Financial Results

CAMBRIDGE, Mass., Nov 04, 2009 (BUSINESS WIRE) -- Javelin Pharmaceuticals, Inc. (NYSE Amex: JAV) announced today that its CEO, Martin J. Driscoll, and Stephen J. Tulipano, CFO, will host a conference call to discuss the Company's quarterly results for the period ending September 30, 2009. The call will be held Tuesday, November 10, 2009 at 8:30am EST.

The Company invites all interested parties to participate. The call will be web cast live through the following URL: ir.javelinpharmaceuticals.com/events.cfm.

CONFERENCE CALL ALERT

Javelin Pharmaceuticals, Inc. Q3 2009 Earnings Call

Date: Tuesday, November 10, 2009

Time: 8:30am EST

Those interested in participating in the call should dial 877-874-1570 within the United States or 719-325-4774 internationally. The call will be archived at the Company's website www.javelinpharmaceuticals.com.

About Javelin Pharmaceuticals, Inc.

With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the acute pain management market. The Company has one marketed drug in the UK and three drug candidates in US Phase 3 clinical development. For additional information about Javelin, please visit the Company's website at <http://www.javelinpharmaceuticals.com>.

Forward Looking Statement:

This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our ability to obtain working capital, our ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies.

JAV-E

SOURCE: Javelin Pharmaceuticals, Inc.

Javelin Pharmaceuticals, Inc.
Stephen J. Tulipano, CPA, 617-349-4500
Chief Financial Officer
stulipano@javelinpharma.com

or

Investor Relations & Media
Rick Pierce, 617-349-4500
Vice President, Investor Relations
rpierce@javelinpharma.com

Copyright Business Wire 2009